Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD, USA.
Crit Care Med. 2010 Feb;38(2):553-61. doi: 10.1097/CCM.0b013e3181cb0a25.
To determine whether intensive care medicine therapies and testing influence hypothalamic-pituitary-adrenal test results. It is routine in intensive care medicine to measure hypothalamic-pituitary-adrenal function, commonly utilizing the adrenocorticotropic hormone stimulation test to diagnose absolute or relative adrenal insufficiency.
Prospective, 96-hr animal study.
Research laboratory.
Twenty-four healthy canines.
Animals were randomized into two groups--awake and unrestrained or treated with intensive care medicine therapies, including sedation, intubation, and mechanical ventilation. Animals were further randomized to receive dexamethasone (or placebo) or undergo either a total of four or seven adrenocorticotropic hormone stimulation tests over 96 hrs.
Sedation, intubation, and mechanical ventilation transiently increased both basal and postadrenocorticotropic hormone total and free cortisol concentrations >2-fold as compared with baseline for the first 24 hrs (p < or = .05 for both). Performance of seven stimulation tests increased both basal and postadrenocorticotropic hormone total and free cortisol concentrations from baseline by >1.5-fold for the duration of the 96-hr study (p < or = .05). Neither sedation, intubation, and mechanical ventilation nor the performance of more stimulation tests affected delta cortisol measurements (total or free cortisol, p = NS). In contrast, dexamethasone suppressed basal total cortisol concentrations by >2-fold (p < or = .005) at all time points and transiently increased delta total cortisol by approximately 35% during the first 24 hrs of the study (p < or = .05).
Total and free cortisol measurements--whether pre- or post- adrenocorticotropic hormone or as a calculated delta--were altered by intensive care therapies or frequent adrenocorticotropic hormone stimulation testing with one exception. Delta free cortisol was the only hypothalamic-pituitary-adrenal measurement unaffected by sedation, intubation, and mechanical ventilation, completion of more adrenocorticotropic hormone stimulation tests, or dexamethasone therapy. These findings support the need to determine normal ranges for hypothalamic-pituitary-adrenal testing in subjects receiving intensive care medicine before establishing laboratory criteria for the diagnosis of relative adrenal insufficiency.
确定重症监护医学治疗和检测是否会影响下丘脑-垂体-肾上腺测试结果。在重症监护医学中,通常测量下丘脑-垂体-肾上腺功能,常用促肾上腺皮质激素刺激试验来诊断绝对或相对肾上腺功能不全。
前瞻性,96 小时动物研究。
研究实验室。
24 只健康犬。
动物随机分为两组——清醒且不受约束或接受重症监护医学治疗,包括镇静、插管和机械通气。动物进一步随机接受地塞米松(或安慰剂)或在 96 小时内接受总共 4 或 7 次促肾上腺皮质激素刺激试验。
镇静、插管和机械通气在最初 24 小时内使基础和促肾上腺皮质激素后总皮质醇和游离皮质醇浓度短暂增加 2 倍以上(p < 或 =.05)。在 96 小时研究期间,进行 7 次刺激试验使基础和促肾上腺皮质激素后总皮质醇和游离皮质醇浓度增加了 1.5 倍以上(p < 或 =.05)。镇静、插管和机械通气或进行更多刺激试验均不影响皮质醇测量的差值(总皮质醇或游离皮质醇,p = NS)。相反,地塞米松在所有时间点均使基础总皮质醇浓度降低 2 倍以上(p < 或 =.005),并在研究的前 24 小时内短暂增加总皮质醇差值约 35%(p < 或 =.05)。
总皮质醇和游离皮质醇测量——无论是促肾上腺皮质激素前或后,还是作为计算的差值——除了一个例外,都被重症监护治疗或频繁的促肾上腺皮质激素刺激试验改变。只有游离皮质醇的 delta 不受镇静、插管和机械通气、完成更多的促肾上腺皮质激素刺激试验或地塞米松治疗的影响。这些发现支持在确定相对肾上腺功能不全的实验室标准之前,需要确定接受重症监护医学治疗的受试者的下丘脑-垂体-肾上腺测试的正常范围。